Respiratory News and Research

RSS

Evidence that elevated blood glucose is a significant risk factor for severe COVID-19

The literature analysis pointed to elevated blood glucose levels as a leading facilitator in the progression of COVID-19. Evidence linking elevated glucose to various steps in the life cycle of the virus and presentation of COVID-19 symptoms were also found.

3 May 2021

SARS-CoV-2 study in human gut organoids

Most of the major life-threatening symptoms of COVID-19 disease are associated with the host's generation of an exacerbated pro-inflammatory immune response. Many studies have correlated the intensity of the immune response with the severity of disease.

3 May 2021

Study shows a protective association between anticoagulants and COVID-19

In a new study, researchers investigated the association between the use of oral anticoagulants and warfarin in COVID-19 disease outcomes. They published their results in a paper on the medRxiv* preprint server.

3 May 2021

Differential NK cell activity found to contribute to SARS-CoV-2 infection resistance

The COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected millions of people worldwide and is the leading cause of mortality in Brazil in 2020 as well as early 2021. Clinical manifestations of COVID-19 disease range from no symptoms and mild flu-like symptoms to severe cases leading to hospitalization and death.

3 May 2021

Monoclonal antibody neutralizes all SARS-CoV-2 variants of concern

Researchers in Canada and the United States have identified a monoclonal antibody that potently neutralizes variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent responsible for the ongoing coronavirus disease 2019 (COVIdD-19) pandemic.

3 May 2021

Researchers demonstrate real-world effectiveness of Johnson & Johnson COVID-19 vaccine

Researchers in the United States and India have conducted a study demonstrating the real-world effectiveness of a single dose of Johnson & Johnson’s Ad26.COV2.S vaccine at preventing infection with severe acute respiratory syndrome coronavirus 2 – the agent that causes coronavirus disease 2019 (COVID-19).

3 May 2021

SARS-CoV-2 antibodies are detectable up to a year after infection, finds study

A team of scientists from the United States has recently investigated the robustness and durability of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in coronavirus disease 2019 (COVID-19) patients. Their findings reveal that COVID-19 patients exhibit a strong anti-SARS-CoV-2 antibody response for up to 1 year and that the robustness of antibody response depends on the patient’s age and disease severity.

3 May 2021

SARS-CoV-2 spike mutations during transmission among humans and to animals

A fascinating new study discusses the 40 mutations that are seen on the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein and their potential effects on viral biology.

3 May 2021

COVID-19 may not have appeared first in China, suggests new genomic study

A new study in Acta Mathematica Scientia suggests that the virus may have originated in multiple countries almost simultaneously, rather than spreading from China to the rest of the world.

3 May 2021

Hopeaphenol inhibits entry of SARS-CoV-2 variants of concern into cells

A new study, released as a preprint on the bioRxiv* server, reports promising results with the natural product hopeaphenol, which successfully prevented the entry of the virus into host cells.

3 May 2021

Class I HLA alleles shape CD8+ T cell repertoire in SARS-CoV-2 infection

An interesting new study discusses how adaptive cellular immunity against the SARS-CoV-2 is dependent on differences in HLA-encoding genes between patients.

3 May 2021

Most long COVID-19 sequelae affect people under 65, finds study

A new study, released as a preprint on the medRxiv* server, discusses the typical symptoms and signs of this syndrome, with the intention of improving the specificity of detection and reporting.

3 May 2021

Planned cesarean deliveries may be associated with lower risk of adverse outcomes

New research shows that planned cesarean deliveries on maternal request are safe for low-risk pregnancies and may be associated with a lower risk of adverse delivery outcomes than planned vaginal deliveries.

3 May 2021

A new SARS-CoV-2 variant (HMN.19B) has been identified in France

New research published in the Centers for Disease Control and Prevention’s journal Emerging Infectious Diseases has confirmed the emergence of a new SARS-CoV-2 variant called HMN.19B from the viral clade 19B in France. The 19B viral clade — which includes the D614G variant — was prevalent in late 2019 but had since been rarely observed since early 2020 because of newer viral clades.

3 May 2021

Vaccine candidate targeting SARS-CoV-2 nucleocapsid protein elicits protective immune response in animal model

New preclinical results from a study led by David Masopust of the University of Minnesota in Minneapolis, USA, show that a Had5-based vaccine targeting the nucleocapsid protein can also elicit a protective immune response.

3 May 2021

Competitive multiplex binding assay can monitor SARS-CoV-2 immune responses using nanobodies

Researchers at the Eberhard Karls University and the University of Tübingen in Germany described 11 unique nanobodies (Nbs) specific for the SARS-CoV-2 spike receptor-binding domain (RBD), of which 8 Nbs potentially inhibit the connection of RBD with the angiotensin-converting enzyme 2 (ACE2).

3 May 2021

SARS-CoV-2’s distinctive "spike" protein plays a key role in the disease itself, shows study

Scientists have known for a while that SARS-CoV-2's distinctive "spike" proteins help the virus infect its host by latching on to healthy cells. Now, a major new study shows that they also play a key role in the disease itself.

3 May 2021

Study finds one-third of COVID-19 patients experience neurological symptoms

The research on the short and long-term effects of COVID-19 disease is ongoing. Still, scientists have found severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) affects the brain causing loss of smell and taste, dizziness, muscle pain, fatigue, and other cognitive impairments. However, it remained unknown why certain people developed neurological symptoms while others did not.

3 May 2021

Low-profile thoracic aortic endograft minimizes complications, increases patient pool

Preliminary results of a clinical trial, presented today at the AATS 101st Annual Meeting, showed that a new, low-profile thoracic aortic endograft is safe and effective in the treatment of descending thoracic aortic aneurysm or penetrating atherosclerotic ulcer (PAU) diseases.

3 May 2021

Study estimates true number of COVID-19 deaths by U.S. county

Every country has been affected by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that has spawned a pandemic. For several factors, the United States has been hit hard by the number of coronavirus cases and death. The country currently leads the world with over 32.4 million infections and more than 577,000 COVID-19 deaths.

3 May 2021

Respiratory News and Research

Evidence that elevated blood glucose is a significant risk factor for severe COVID-19

SARS-CoV-2 study in human gut organoids

Study shows a protective association between anticoagulants and COVID-19

Differential NK cell activity found to contribute to SARS-CoV-2 infection resistance

Monoclonal antibody neutralizes all SARS-CoV-2 variants of concern

Researchers demonstrate real-world effectiveness of Johnson & Johnson COVID-19 vaccine

SARS-CoV-2 antibodies are detectable up to a year after infection, finds study

SARS-CoV-2 spike mutations during transmission among humans and to animals

COVID-19 may not have appeared first in China, suggests new genomic study

Hopeaphenol inhibits entry of SARS-CoV-2 variants of concern into cells

Class I HLA alleles shape CD8+ T cell repertoire in SARS-CoV-2 infection

Most long COVID-19 sequelae affect people under 65, finds study

Planned cesarean deliveries may be associated with lower risk of adverse outcomes

A new SARS-CoV-2 variant (HMN.19B) has been identified in France

Vaccine candidate targeting SARS-CoV-2 nucleocapsid protein elicits protective immune response in animal model

Competitive multiplex binding assay can monitor SARS-CoV-2 immune responses using nanobodies

SARS-CoV-2’s distinctive "spike" protein plays a key role in the disease itself, shows study

Study finds one-third of COVID-19 patients experience neurological symptoms

Low-profile thoracic aortic endograft minimizes complications, increases patient pool

Study estimates true number of COVID-19 deaths by U.S. county

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News